BioWorld

Oct. 20, 2003

FDA Signs Off On Namenda For Moderate To Severe Alzheimer's

Patients suffering from a seemingly hopeless affliction, and those around them, might gain a glimmer of hope on news of the FDA's approval of Namenda (memantine HCL) for Alzheimer's disease. (BioWorld Today) Read More

President's Council Questions Biotech's Use 'Beyond Therapy'

Listeria monocytogenes Bacteria Pick, Choose, Young, Old, Pregnant As Victims Of Low-Virulence Death

Advancis IPO Raises $60M; Biotech Firms Wait In Wings

Correction

Durect Stock Falls 35 Percent On Likely Phase III Trial Delay

Genelabs Rakes In $27.4M For Prestara, Hepatitis C Programs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...